製品番号: HY-B0250

ラミブジン

(別名: Lamivudine; BCH-189)

19 Cited Publications

カスタマーレビュー

Based on 19 publication(s) in Google Scholar

Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.97%
CAS 番号: 134678-17-4
分子式: C₈H₁₁N₃O₃S
分子量:229.26

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Lamivudine 構造式

CAS 番号: 134678-17-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (19)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

HIV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	CC₅₀	>1000 μM Compound: 3TC	Toxicity in human C8166 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Toxicity in human C8166 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31310115]
Caco-2	IC₅₀	>250 μM Compound: 5, 3TC	Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
CCRF-CEM	IC₅₀	>100 μM Compound: 3TC	In vitro cytotoxicity against CEM cells In vitro cytotoxicity against CEM cells	[PMID: 11052795]
CCRF-CEM	CC₅₀	100 μM Compound: lamivudine	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	[PMID: 15615545]
CCRF-CEM	IC₅₀	>100 μM Compound: 3TC, Epivir	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay	[PMID: 21700368]
CCRF-CEM	CC₅₀	>250 μM Compound: 5, 3TC	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 24177359]
CCRF-CEM	EC₅₀	0.099 μM Compound: 5, 3TC	Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	EC₅₀	0.18 μM Compound: 5, 3TC	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	IC₅₀	>250 μM Compound: 5, 3TC	Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
CCRF-CEM	IC₅₀	>250 μM Compound: 5, 3TC	Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
CCRF-CEM	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human CEM cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay Cytotoxicity against human CEM cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay	[PMID: 28094179]
CCRF-CEM	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human CEM cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay Cytotoxicity against human CEM cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay	[PMID: 28688280]
CCRF-CEM	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay	[PMID: 33421915]
CCRF-CEM	CC₅₀	>100 μM Compound: (-)-BCH-189; (-)-3TC	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 37393791]
CCRF-CEM	IC₅₀	>100 μM Compound: 3TC	The cytotoxicity against CEM cells The cytotoxicity against CEM cells	[PMID: 9301659]
CCRF-CEM	IC₅₀	50 μM Compound: beta-L-oxathiolanecytosine(3TC)	Compound was evaluated for cytotoxicity by inhibition of mitochondrial DNA synthesis Compound was evaluated for cytotoxicity by inhibition of mitochondrial DNA synthesis	10.1016/0960-894X(95)00343-R
CCRF-CEM	IC₅₀	50 μM Compound: beta-L-oxathiolanecytosine(3TC)	Cytotoxicity in H1 CEM cells Cytotoxicity in H1 CEM cells	10.1016/0960-894X(95)00343-R
CCRF-CEM	CC₅₀	363 μM Compound: (-)3TC	Antiviral activity in CEM cells expressed as CC50 Antiviral activity in CEM cells expressed as CC50	10.1016/S0960-894X(97)00178-9
CCRF-CEM	CC₅₀	363 μM Compound: 3TC	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	10.1016/S0960-894X(97)00178-9
CEM-SS	ED₅₀	0.36 μM Compound: 3TC	Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay	[PMID: 15217281]
CEM-SS	EC₅₀	200 nM Compound: 12, 3TC	Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay	[PMID: 22858097]
CHO	IC₅₀	54.2 μM Compound: lamivudine	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
COLO 320	IC₅₀	>250 μM Compound: 5, 3TC	Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
H9	EC₅₀	0.06 μM Compound: 3TC, NSC-697911, (2R-cis)-lamivudine	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.06 μM Compound: 3TC, NSC-697911, (2R-cis)-lamivudine	Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	CC₅₀	>200 μM Compound: Lamivudine	Cytotoxicity against human H9 cells assessed as cell viability incubated for 7 days by MTT colorimetric assay Cytotoxicity against human H9 cells assessed as cell viability incubated for 7 days by MTT colorimetric assay	[PMID: 34245947]
HEK293	EC₅₀	>300 μM Compound: Lamivudine	Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	3.25 μM Compound: Lamivudine	Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	3.54 μM Compound: Lamivudine	Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	3.9 μM Compound: Lamivudine	Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	4.06 μM Compound: Lamivudine	Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	4.24 μM Compound: Lamivudine	Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	4.48 μM Compound: Lamivudine	Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	4.68 μM Compound: Lamivudine	Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	4.78 μM Compound: Lamivudine	Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	5.43 μM Compound: Lamivudine	Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	7.16 μM Compound: Lamivudine	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	[PMID: 20308377]
HEK293	EC₅₀	0.3 μM Compound: 3TC	Antiviral activity against VSVG pseudotyped HIV1 infected in HEK293 cells preincubated for 3 hrs followed by compound washout and subsequent compound redosing and measured after 72 hrs by luciferase reporter gene based assay Antiviral activity against VSVG pseudotyped HIV1 infected in HEK293 cells preincubated for 3 hrs followed by compound washout and subsequent compound redosing and measured after 72 hrs by luciferase reporter gene based assay	[PMID: 32678592]
HEK293	CC₅₀	≥25 μM Compound: 3TC	Cytotoxicity against HEK293 cells assessed as cell viability by MTT assay Cytotoxicity against HEK293 cells assessed as cell viability by MTT assay	[PMID: 32678592]
HEK-293T	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HEK-293T	EC₅₀	>20000 nM Compound: 3TC	Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay	[PMID: 22148316]
HEK-293T	CC₅₀	>100000 nM Compound: 3TC	Cytotoxicity against HEK293T cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability by MTT assay	[PMID: 37535016]
HeLa	IC₅₀	>60 μM Compound: 3TC	Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	0.78 μM Compound: 3TC	Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	IC₅₀	60.5 μM Compound: 3TC	Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication	[PMID: 19596885]
HeLa	EC₅₀	>436 μM Compound: 3TC, Lamivudine	Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay	[PMID: 22352809]
HeLa	EC₅₀	11.3 μM Compound: 3TC, Lamivudine	Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay	[PMID: 22352809]
HeLa	EC₅₀	32.7 μM Compound: 3TC, Lamivudine	Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay	[PMID: 22352809]
HeLa	EC₅₀	>436.6 μM Compound: 1, lamivudine, 3TC	Cytotoxicity against human HeLa P4/R5 cells incubated for 2 hrs followed by compound-wash out measured after 46 hrs by MTS assay Cytotoxicity against human HeLa P4/R5 cells incubated for 2 hrs followed by compound-wash out measured after 46 hrs by MTS assay	[PMID: 22533850]
HeLa	EC₅₀	11.4 μM Compound: 1, lamivudine, 3TC	Antiviral activity against HIV1 BaL assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay Antiviral activity against HIV1 BaL assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay	[PMID: 22533850]
HeLa	EC₅₀	32.7 μM Compound: 1, lamivudine, 3TC	Antiviral activity against HIV1 3B assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay Antiviral activity against HIV1 3B assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay	[PMID: 22533850]
HeLa	IC₅₀	>250 μM Compound: 5, 3TC	Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
HeLa	IC₅₀	>250 μM Compound: 5, 3TC	Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
HeLa	CC₅₀	>20 μM Compound: Lamivudine	Cytotoxicity against mock-infected human HeLa cells by MTT assay Cytotoxicity against mock-infected human HeLa cells by MTT assay	[PMID: 25682562]
Hepatoblastoma cell line	CC₅₀	1884 μM Compound: 3TC	Cytotoxic concentration against Hepatitis B virus in human hepatoblastoma cell line Cytotoxic concentration against Hepatitis B virus in human hepatoblastoma cell line	[PMID: 9622558]
Hepatoblastoma cell line	EC₅₀	0.07 μM Compound: 3TC	Effective concentration against Hepatitis B virus in human hepatoblastoma cell line Effective concentration against Hepatitis B virus in human hepatoblastoma cell line	[PMID: 9622558]
Hepatocyte	EC₅₀	0.01 μg/mL Compound: 3-TC(Lamivudine)	Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures	[PMID: 11985471]
Hepatocyte	EC₅₀	0.04 μM Compound: 3-TC	Inhibition of duck HBV transfected in primary duck hepatocytes Inhibition of duck HBV transfected in primary duck hepatocytes	[PMID: 16539393]
Hepatocyte	EC₅₀	0.04 μM Compound: 3-TC	Antiviral activity against duck HBV in primary duck hepatocytes Antiviral activity against duck HBV in primary duck hepatocytes	[PMID: 16759112]
Hepatocyte	EC₅₀	<0.044 μM Compound: 3-TC, Lamivudine	Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication	[PMID: 20857959]
Hepatocyte	EC₅₀	0.05 μg/mL Compound: 3-TC	Antiviral activity against HBV infected in duck primary hepatocytes Antiviral activity against HBV infected in duck primary hepatocytes	[PMID: 20863701]
Hepatocyte	EC₅₀	0.05 μg/mL Compound: 3-TC, Lamivudine	Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication after 2 days Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication after 2 days	[PMID: 20869253]
Hepatocyte	EC₅₀	0.05 μg/mL Compound: Lamivudine, 3-TC	Antiviral activity against Duck hepatitis B virus infected in pekin duck primary hepatocytes assessed as inhibition of viral replication Antiviral activity against Duck hepatitis B virus infected in pekin duck primary hepatocytes assessed as inhibition of viral replication	[PMID: 22985854]
Hepatocyte	CC₅₀	>400 μM Compound: 3TC	Compound was tested for its cytotoxicity against duck hepatitis B virus in duck fetal hepatocytes culture Compound was tested for its cytotoxicity against duck hepatitis B virus in duck fetal hepatocytes culture	10.1016/0960-894X(96)00316-2
Hepatocyte	IC₅₀	0.1 μM Compound: 3TC	Compound was tested for its antiviral activity against hepatitis B virus(DHBV) in duck fetal hepatocytes culture Compound was tested for its antiviral activity against hepatitis B virus(DHBV) in duck fetal hepatocytes culture	10.1016/0960-894X(96)00316-2
Hepatoma cell line	EC₅₀	0.01 μM Compound: beta-L-oxathiolanecytosine(3TC)	Antiviral activity against hepatitis B virus in human hepatoma cell line (2.2.15 cells) Antiviral activity against hepatitis B virus in human hepatoma cell line (2.2.15 cells)	10.1016/0960-894X(95)00343-R
HepG2	EC₅₀	0.4 μM Compound: 3TC (2'-deoxy-3'thiacytidine)	In vitro concentration required to inhibit HBV DNA secretion by HepG2.2.15 transfected by HBV In vitro concentration required to inhibit HBV DNA secretion by HepG2.2.15 transfected by HBV	[PMID: 12852943]
HepG2	EC₅₀	0.2 μM Compound: 3TC	Effective concentration to inhibit hepatitis B virus cytopathicity in HepG2.2.15 cells was determined in vitro Effective concentration to inhibit hepatitis B virus cytopathicity in HepG2.2.15 cells was determined in vitro	[PMID: 14971898]
HepG2	CC₅₀	2159 μM Compound: 3TC	Cytotoxicity against human hepatoblastoma 2.2.15 cells Cytotoxicity against human hepatoblastoma 2.2.15 cells	[PMID: 16213713]
HepG2	CC₅₀	>1000 μM Compound: lamivudine	Cytotoxicity against HepG2.2.15 cells Cytotoxicity against HepG2.2.15 cells	[PMID: 16854087]
HepG2	CC₅₀	>100 μM Compound: lamivudine	Cytotoxicity against 2.2.15 cells Cytotoxicity against 2.2.15 cells	[PMID: 17004726]
HepG2	CC₅₀	1200 μM Compound: 3TC, lamivudine	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 17404006]
HepG2	CC₅₀	100 μM Compound: 3TC	Cytotoxicity against HBV transfected human HepG2 cells by MTT assay Cytotoxicity against HBV transfected human HepG2 cells by MTT assay	[PMID: 17488817]
HepG2	IC₅₀	>1 μM Compound: 3TC	Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay	[PMID: 17488817]
HepG2	CC₅₀	>25 μM Compound: 3TC	Cytotoxicity against human HepG2 cells after 3 days by neutral red dye uptake assay Cytotoxicity against human HepG2 cells after 3 days by neutral red dye uptake assay	[PMID: 21333535]
HepG2	EC₅₀	>2.5 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2 cells assessed as reduction in viral DNA after 3 days by Southern blotting Antiviral activity against Hepatitis B virus infected in human HepG2 cells assessed as reduction in viral DNA after 3 days by Southern blotting	[PMID: 21333535]
HepG2	CC₅₀	>10 μM Compound: 3TC	Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method	[PMID: 25849312]
HepG2	CC₅₀	>10 μM Compound: 3TC	Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method	[PMID: 25849312]
HepG2	CC₅₀	>10 μM Compound: 3TC	Cytotoxicity against human HepG2 cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay Cytotoxicity against human HepG2 cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay	[PMID: 28094179]
HepG2	IC₅₀	>10 μM Compound: 3TC	Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method	[PMID: 28595015]
HepG2	IC₅₀	>10 μM Compound: 3TC	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method	[PMID: 28595015]
HepG2	CC₅₀	>10 μM Compound: 3TC	Cytotoxicity against human HepG2 cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay Cytotoxicity against human HepG2 cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay	[PMID: 28688280]
HepG2	IC₅₀	>10 μM Compound: 3TC	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	[PMID: 30653317]
HepG2	IC₅₀	>10 μM Compound: 3TC	Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control	[PMID: 30653317]
HepG2	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity in human HepG2 cells assessed as induction of cell killing Cytotoxicity in human HepG2 cells assessed as induction of cell killing	[PMID: 32421339]
HepG2	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 33421915]
HepG2	CC₅₀	>500 μM Compound: 3TC	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 3 days by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 3 days by MTT assay	[PMID: 35776695]
HepG2	EC₅₀	0.008 μM Compound: 3TC	In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells	[PMID: 9301659]
HepG2	EC₅₀	0.2 μM Compound: 1	Tested for the effective concentration required to inhibit HBV in HepG2.2.15 human liver cells Tested for the effective concentration required to inhibit HBV in HepG2.2.15 human liver cells	10.1016/S0960-894X(96)00594-X
HepG2	EC₅₀	0.038 μM Compound: Lamivudine (3TC)	Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro	10.1016/S0960-894X(97)00422-8
HepG2	IC₅₀	1792 μM Compound: Lamivudine (3TC)	Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro	10.1016/S0960-894X(97)00422-8
HepG2 2.2.15	EC₅₀	0.008 μM Compound: 3TC	Antiviral activity against Hepatitis B virus (HBV) in 2.2.15 cells Antiviral activity against Hepatitis B virus (HBV) in 2.2.15 cells	[PMID: 11052795]
HepG2 2.2.15	EC₅₀	0.02 μM Compound: lamivudine	Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay	[PMID: 15615545]
HepG2 2.2.15	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxic concentration to inhibit replication in 2.2.15 cells Cytotoxic concentration to inhibit replication in 2.2.15 cells	[PMID: 15634003]
HepG2 2.2.15	EC₅₀	0.05 μM Compound: Lamivudine	Effective concentration required to inhibit hepatitis B virus replication in 2.2.15 cells in DNA hybridization assay Effective concentration required to inhibit hepatitis B virus replication in 2.2.15 cells in DNA hybridization assay	[PMID: 15634003]
HepG2 2.2.15	CC₅₀	2675 μM Compound: Lamivudine	Cytotoxic concentration against HBV replication in 2.2.15 cell culture Cytotoxic concentration against HBV replication in 2.2.15 cell culture	[PMID: 16033283]
HepG2 2.2.15	EC₅₀	0.06 μM Compound: Lamivudine	Effective concentrations at which 2-fold depression of extracellular virion DNA (HBV) was observed in 2.2.15 Cells Effective concentrations at which 2-fold depression of extracellular virion DNA (HBV) was observed in 2.2.15 Cells	[PMID: 16033283]
HepG2 2.2.15	EC₅₀	0.23 μM Compound: Lamivudine	Effective concentrations at which 10-fold depression of intracellular intermediates of HBV DNA was observed in 2.2.15 Cells Effective concentrations at which 10-fold depression of intracellular intermediates of HBV DNA was observed in 2.2.15 Cells	[PMID: 16033283]
HepG2 2.2.15	EC₅₀	0.048 μM Compound: 3TC	Inhibition of synthesis of extracellular virion DNA release in cultured human hepatoblastoma 2.2.15 cells Inhibition of synthesis of extracellular virion DNA release in cultured human hepatoblastoma 2.2.15 cells	[PMID: 16213713]
HepG2 2.2.15	EC₅₀	0.251 μM Compound: 3TC	Inhibition of synthesis of intracellular HBV DNA replicative intermediates in cultured human hepatoblastoma 2.2.15 cells Inhibition of synthesis of intracellular HBV DNA replicative intermediates in cultured human hepatoblastoma 2.2.15 cells	[PMID: 16213713]
HepG2 2.2.15	EC₅₀	2.1 μM Compound: 3-TC	Inhibition of wild type HBV transfected in human hepatoblastoma 2.2.15 cells Inhibition of wild type HBV transfected in human hepatoblastoma 2.2.15 cells	[PMID: 16539393]
HepG2 2.2.15	EC₅₀	2.1 μM Compound: 3-TC	Antiviral activity against wild type HBV in human hepatoma 2.2.15 cells Antiviral activity against wild type HBV in human hepatoma 2.2.15 cells	[PMID: 16759112]
HepG2 2.2.15	EC₅₀	0.02 μM Compound: lamivudine	Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay	[PMID: 17004726]
HepG2 2.2.15	EC₅₀	0.1 μM Compound: 3TC, lamivudine	Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR	[PMID: 17404006]
HepG2 2.2.15	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay	[PMID: 17488817]
HepG2 2.2.15	IC₅₀	0.05 μM Compound: 3TC	Antiviral activity against HBV in ayw wild type HepG2(2.2.15) cells assessed as inhibition of viral DNA replication Antiviral activity against HBV in ayw wild type HepG2(2.2.15) cells assessed as inhibition of viral DNA replication	[PMID: 17488817]
HepG2 2.2.15	CC₅₀	>1000 μM Compound: lamivudine	Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay	[PMID: 17499889]
HepG2 2.2.15	CC₅₀	30 mM Compound: Lamivudine	Cytotoxicity against human Hep G2.2.15 cells Cytotoxicity against human Hep G2.2.15 cells	[PMID: 17723297]
HepG2 2.2.15	IC₅₀	11.7 mM Compound: Lamivudine	Antiviral activity against HBV transfected Hep G2.2.15 cells assessed as inhibition of surface antigen HBsAg secretion Antiviral activity against HBV transfected Hep G2.2.15 cells assessed as inhibition of surface antigen HBsAg secretion	[PMID: 17723297]
HepG2 2.2.15	IC₅₀	25.9 mM Compound: Lamivudine	Antiviral activity against HBV transfected Hep G2.2.15 cells assessed as inhibition of e antigen HBsAg secretion Antiviral activity against HBV transfected Hep G2.2.15 cells assessed as inhibition of e antigen HBsAg secretion	[PMID: 17723297]
HepG2 2.2.15	CC₅₀	30 mM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells by MTT assay Cytotoxicity against human HepG2.2.15 cells by MTT assay	[PMID: 18396905]
HepG2 2.2.15	IC₅₀	11.7 mM Compound: 3TC	Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion in HepG2.2.15 cells by ELISA Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion in HepG2.2.15 cells by ELISA	[PMID: 18396905]
HepG2 2.2.15	IC₅₀	25.9 mM Compound: 3TC	Antiviral activity against HBV assessed as inhibition of viral e-antigen secretion in HepG2.2.15 cells by ELISA Antiviral activity against HBV assessed as inhibition of viral e-antigen secretion in HepG2.2.15 cells by ELISA	[PMID: 18396905]
HepG2 2.2.15	CC₅₀	30 mM Compound: 3TC	Cytotoxicity against human Hep G2.2.15 cells Cytotoxicity against human Hep G2.2.15 cells	[PMID: 18524583]
HepG2 2.2.15	IC₅₀	11.7 mM Compound: 3TC	Antiviral activity against hepatitis B virus infected Hep G2.2.15 cells assessed as inhibition of HBsAg secretion Antiviral activity against hepatitis B virus infected Hep G2.2.15 cells assessed as inhibition of HBsAg secretion	[PMID: 18524583]
HepG2 2.2.15	IC₅₀	25.9 mM Compound: 3TC	Antiviral activity against hepatitis B virus infected Hep G2.2.15 cells assessed as inhibition of HBeAg secretion Antiviral activity against hepatitis B virus infected Hep G2.2.15 cells assessed as inhibition of HBeAg secretion	[PMID: 18524583]
HepG2 2.2.15	EC₅₀	0.048 μM Compound: 3TC	Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as extracellular HBV virion DNA level after 24 hrs Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as extracellular HBV virion DNA level after 24 hrs	[PMID: 19072694]
HepG2 2.2.15	EC₅₀	0.15 μM Compound: 3TC	Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as replication intermediates after 24 hrs Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as replication intermediates after 24 hrs	[PMID: 19072694]
HepG2 2.2.15	IC₅₀	>2000 μM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells assessed as uptake of neutral red dye after 24 hrs Cytotoxicity against human HepG2(2.2.15) cells assessed as uptake of neutral red dye after 24 hrs	[PMID: 19072694]
HepG2 2.2.15	CC₅₀	31 mM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 19289281]
HepG2 2.2.15	IC₅₀	82.42 μM Compound: Lamivudine	Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral genome replication after 9 days by Southern blot hybridization Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral genome replication after 9 days by Southern blot hybridization	[PMID: 19307124]
HepG2 2.2.15	CC₅₀	2183.1 μM Compound: lamivudine	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye staining Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye staining	[PMID: 19457674]
HepG2 2.2.15	IC₅₀	240 μM Compound: lamivudine	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication	[PMID: 19457674]
HepG2 2.2.15	CC₅₀	35 mM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 19853440]
HepG2 2.2.15	IC₅₀	0.22 μM Compound: Lamivudine	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication	[PMID: 19897363]
HepG2 2.2.15	EC₅₀	>100 μM Compound: 3TC	Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	>100 μM Compound: 3TC	Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	>100 μM Compound: 3TC	Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	0.2 μM Compound: 3TC	Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	0.2 μM Compound: 3TC	Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	5.3 μM Compound: 3TC	Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	IC₅₀	14.8 μg/mL Compound: Lamivudine	Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 8 days by radio immunoassay Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 8 days by radio immunoassay	[PMID: 20149495]
HepG2 2.2.15	CC₅₀	5 μM Compound: Lamivudine	Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay	[PMID: 20639110]
HepG2 2.2.15	IC₅₀	0.16 μM Compound: Lamivudine	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis after 8 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis after 8 days by RT-PCR analysis	[PMID: 20639110]
HepG2 2.2.15	EC₅₀	0.2 μg/mL Compound: 3-TC	Antiviral activity against HBV infected in human 2.2.15 cell Antiviral activity against HBV infected in human 2.2.15 cell	[PMID: 20863701]
HepG2 2.2.15	EC₅₀	0.2 μg/mL Compound: 3-TC, Lamivudine	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 2 days Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 2 days	[PMID: 20869253]
HepG2 2.2.15	CC₅₀	2183.1 μM Compound: Lamivudine	Cytotoxicity against human HepG2(2.2.15) after 9 days by neutral dye uptake method Cytotoxicity against human HepG2(2.2.15) after 9 days by neutral dye uptake method	[PMID: 21074429]
HepG2 2.2.15	IC₅₀	240 μM Compound: Lamivudine	Antiviral activity against Hepatitis B virus infected in HepG2.2.15 assessed as inhibition of HBV replication by quantitative Southern blot hybridization analysis Antiviral activity against Hepatitis B virus infected in HepG2.2.15 assessed as inhibition of HBV replication by quantitative Southern blot hybridization analysis	[PMID: 21074429]
HepG2 2.2.15	CC₅₀	30 mM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 21145140]
HepG2 2.2.15	IC₅₀	27 mM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion after 6 days by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion after 6 days by ELISA	[PMID: 21145140]
HepG2 2.2.15	IC₅₀	30 mM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion after 6 days by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion after 6 days by ELISA	[PMID: 21145140]
HepG2 2.2.15	IC₅₀	4.51 μg/mL Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by semi-quantitative EIA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by semi-quantitative EIA	[PMID: 21183354]
HepG2 2.2.15	CC₅₀	2128 μM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay	[PMID: 21333535]
HepG2 2.2.15	EC₅₀	0.06 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting	[PMID: 21333535]
HepG2 2.2.15	CC₅₀	2400 μM Compound: lamivudine	Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay	[PMID: 21401115]
HepG2 2.2.15	IC₅₀	58 μM Compound: lamivudine	Antiviral activity against HBV transfected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion by ELISA Antiviral activity against HBV transfected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion by ELISA	[PMID: 21401115]
HepG2 2.2.15	CC₅₀	1174 μM Compound: lamivudine	Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay	[PMID: 21524588]
HepG2 2.2.15	IC₅₀	0.33 μM Compound: lamivudine	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis	[PMID: 21524588]
HepG2 2.2.15	CC₅₀	33.25 mM Compound: 3TC	Cytotoxicity in human HepG2(2.2.15) cells after 72 hrs by MTT assay Cytotoxicity in human HepG2(2.2.15) cells after 72 hrs by MTT assay	[PMID: 21823575]
HepG2 2.2.15	IC₅₀	25.94 mM Compound: 3TC	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBsAg antigen secretion after 72 hrs by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBsAg antigen secretion after 72 hrs by ELISA	[PMID: 21823575]
HepG2 2.2.15	IC₅₀	30.26 mM Compound: 3TC	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBeAg antigen secretion after 72 hrs by ELISA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBeAg antigen secretion after 72 hrs by ELISA	[PMID: 21823575]
HepG2 2.2.15	IC₅₀	82.42 μM Compound: Lamivudine	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by measuring HBsAg and HBeAg production after 9 days by EIA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by measuring HBsAg and HBeAg production after 9 days by EIA	[PMID: 21872478]
HepG2 2.2.15	EC₅₀	>100 μM Compound: Lamivudine	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	>100 μM Compound: Lamivudine	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	>100 μM Compound: Lamivudine	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	>500 μM Compound: Lamivudine	Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	0.2 μM Compound: Lamivudine	Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	0.2 μM Compound: Lamivudine	Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	1.5 μM Compound: Lamivudine	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	[PMID: 21930377]
HepG2 2.2.15	EC₅₀	0.2 μg/mL Compound: Lamivudine, 3-TC	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication	[PMID: 22985854]
HepG2 2.2.15	IC₅₀	405.6 μM Compound: 3TC	Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA	[PMID: 23369536]
HepG2 2.2.15	CC₅₀	>1000 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay	[PMID: 23369536]
HepG2 2.2.15	IC₅₀	>1000 μM Compound: 3TC	Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA	[PMID: 23369536]
HepG2 2.2.15	CC₅₀	391.21 μM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay	[PMID: 23434030]
HepG2 2.2.15	IC₅₀	141.32 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA	[PMID: 23434030]
HepG2 2.2.15	IC₅₀	175.93 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA	[PMID: 23434030]
HepG2 2.2.15	IC₅₀	99.45 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis	[PMID: 23434030]
HepG2 2.2.15	CC₅₀	31.18 mM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 23434420]
HepG2 2.2.15	IC₅₀	28.82 mM Compound: 3TC	Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion	[PMID: 23434420]
HepG2 2.2.15	IC₅₀	30.35 mM Compound: 3TC	Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBeAg secretion Antiviral activity against Hepatitis B virus-infected human HepG2(2.2.15) cells assessed as inhibition of HBeAg secretion	[PMID: 23434420]
HepG2 2.2.15	IC₅₀	343.2 μM Compound: Lamivudine	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production	[PMID: 24549242]
HepG2 2.2.15	IC₅₀	14.17 μM Compound: 3TC	Antiviral activity against hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral replication Antiviral activity against hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral replication	[PMID: 25127104]
HepG2 2.2.15	IC₅₀	14.17 μmol Compound: 3TC	Antiviral activity against hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral replication Antiviral activity against hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral replication	[PMID: 25127104]
HepG2 2.2.15	IC₅₀	7.63 μM Compound: 3TC	Decrease in HBV viral DNA replication in human HepG2(2.2.15) cells at 0.75 to 3 uM after 72 hrs by real-time PCR analysis Decrease in HBV viral DNA replication in human HepG2(2.2.15) cells at 0.75 to 3 uM after 72 hrs by real-time PCR analysis	[PMID: 25461891]
HepG2 2.2.15	IC₅₀	41 μg/mL Compound: 3TC	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication	[PMID: 25600408]
HepG2 2.2.15	IC₅₀	49.13 μg/mL Compound: 3TC	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion by EIA Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion by EIA	[PMID: 25600408]
HepG2 2.2.15	CC₅₀	568.25 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTT assay Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTT assay	[PMID: 25847765]
HepG2 2.2.15	IC₅₀	234.7 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA	[PMID: 25847765]
HepG2 2.2.15	IC₅₀	267.16 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA	[PMID: 25847765]
HepG2 2.2.15	IC₅₀	6.86 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication by real-time fluorescence quantitative PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication by real-time fluorescence quantitative PCR analysis	[PMID: 25847765]
HepG2 2.2.15	IC₅₀	0.039 μM Compound: lamivudine	Antiviral activity against HBV infected in human HepG22.2.15 cells after 3 days by neutral red dye-based plaque reduction assay Antiviral activity against HBV infected in human HepG22.2.15 cells after 3 days by neutral red dye-based plaque reduction assay	[PMID: 26260336]
HepG2 2.2.15	EC₅₀	2399 μM Compound: 3TC	Antiviral activity against HBV infected in human HepG2(2.2.15) cells Antiviral activity against HBV infected in human HepG2(2.2.15) cells	[PMID: 26372075]
HepG2 2.2.15	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay	[PMID: 27484509]
HepG2 2.2.15	CC₅₀	>2 μM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability by MTS assay	[PMID: 27748590]
HepG2 2.2.15	CC₅₀	1020 μM Compound: Lamivudine	Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay	[PMID: 28082068]
HepG2 2.2.15	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 8 days by CCK-8 assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 8 days by CCK-8 assay	[PMID: 28494252]
HepG2 2.2.15	CC₅₀	>2 μM Compound: Lamivudine	Cytotoxicity against human HepG2.2.15 cells assessed as cell viability by tetrazolium dye uptake assay Cytotoxicity against human HepG2.2.15 cells assessed as cell viability by tetrazolium dye uptake assay	[PMID: 28682067]
HepG2 2.2.15	CC₅₀	>1000 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells after 9 days by MTT assay Cytotoxicity against human HepG2.2.15 cells after 9 days by MTT assay	[PMID: 29174810]
HepG2 2.2.15	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29288943]
HepG2 2.2.15	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells assessed as cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2.2.15 cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 31091479]
HepG2 2.2.15	CC₅₀	>218.1 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells infected with HBV Cytotoxicity against human HepG2.2.15 cells infected with HBV	[PMID: 31223460]
HepG2 2.2.15	EC₅₀	0.0038 μM Compound: 3TC	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis	[PMID: 32421339]
HepG2 2.2.15	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay	[PMID: 32712535]
HepG2 2.2.15	CC₅₀	>100 μM Compound: 3 TC	Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32791397]
HepG2 2.2.15	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human HepG2 2.2.15 cell line assessed as cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 2.2.15 cell line assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 33285406]
HepG2 2.2.15	CC₅₀	>100 μM Compound: LAM	Cytotoxicity against human HepG2 2.2.15 cells infected with Hepatitis B virus assessed as reduction in cell growth by CCK8 assay Cytotoxicity against human HepG2 2.2.15 cells infected with Hepatitis B virus assessed as reduction in cell growth by CCK8 assay	[PMID: 35123297]
HepG2 2.2.15	IC₅₀	<0.1 μM Compound: LAM	Antiviral activity against Hepatitis B virus infected in human HepG2 2.2.15 cells assessed as inhibition of DNA replication Antiviral activity against Hepatitis B virus infected in human HepG2 2.2.15 cells assessed as inhibition of DNA replication	[PMID: 35123297]
HepG2 2.2.15	CC₅₀	>2 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 1 to 4 hrs by MTS uptake assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 1 to 4 hrs by MTS uptake assay	[PMID: 35754374]
HepG2 2.2.15	CC₅₀	2124 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability by neutral red uptake assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability by neutral red uptake assay	[PMID: 35754374]
HepG2 2.2.15	CC₅₀	2124 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability	[PMID: 35754374]
HepG2 2.2.15	CC₅₀	>20 μM Compound: LAM	Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 36228413]
HepG2 2.2.15	CC₅₀	>2 μM Compound: 3TC	Cytotoxicity against human HepG2.2.15 cells Cytotoxicity against human HepG2.2.15 cells	[PMID: 36898483]
HepG2 2.2.15	CC₅₀	>2 μM Compound: 3TC	Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability by MTS assay	[PMID: 37611244]
HepG2 2.2.15	CC₅₀	>100 μM Compound: LAM	Cytotoxicity against human HepG2.2.15 cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human HepG2.2.15 cells incubated for 72 hrs by CCK8 assay	[PMID: 38865744]
HepG2 2.2.15	IC₅₀	>100 μM Compound: LAM	Inhibition of HBsAg secretion in human HepG2.2.15 cells treated for 6 days with replacement of medium containing compound on every 2 days by RT-PCR analysis Inhibition of HBsAg secretion in human HepG2.2.15 cells treated for 6 days with replacement of medium containing compound on every 2 days by RT-PCR analysis	[PMID: 38865744]
HL-60	CC₅₀	1400 μM Compound: 3TC, lamivudine	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 17404006]
Huh-7	EC₅₀	1 μM Compound: lamivudine, LAM	Inhibition of wild type HBV replication in Huh7 cells Inhibition of wild type HBV replication in Huh7 cells	[PMID: 17371827]
Huh-7	CC₅₀	>1000 μM Compound: lamivudine, LAM	Effect on cell viability in human Huh7 cells Effect on cell viability in human Huh7 cells	[PMID: 17371827]
Huh-7	EC₅₀	0.03 μM Compound: LMV	Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days	[PMID: 17438047]
Huh-7	EC₅₀	0.03 μM Compound: LMV	Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days	[PMID: 17438047]
Huh-7	EC₅₀	0.41 μM Compound: LMV	Antiviral activity against HBV genotype D in human Huh7 cells assessed as inhibition of viral replication after 5 days Antiviral activity against HBV genotype D in human Huh7 cells assessed as inhibition of viral replication after 5 days	[PMID: 17438047]
Huh-7	EC₅₀	0.46 μM Compound: LMV	Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days	[PMID: 17438047]
Huh-7	EC₅₀	>100 μM Compound: 3TC	Antiviral activity against lamivudine-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against lamivudine-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	>100 μM Compound: 3TC	Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	>100 μM Compound: 3TC	Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	0.2 μM Compound: 3TC	Antiviral activity against lamivudine-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against lamivudine-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	0.3 μM Compound: 3TC	Antiviral activity against lamivudine-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against lamivudine-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.3 μM Compound: 3TC	Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.5 μM Compound: 3TC	Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.6 μM Compound: 3TC	Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.6 μM Compound: 3TC	Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	1.8 μM Compound: 3TC	Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	10 μM Compound: 3TC	Antiviral activity against lamivudine-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against lamivudine-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	7.7 μM Compound: 3TC	Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay	[PMID: 19072694]
Huh-7	EC₅₀	>100 μM Compound: Lamivudine	Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	>100 μM Compound: Lamivudine	Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	>100 μM Compound: Lamivudine	Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	0.2 μM Compound: Lamivudine	Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	0.3 μM Compound: Lamivudine	Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	16 μM Compound: Lamivudine	Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	CC₅₀	>873 μM Compound: 3-TC, Lamivudine	Cytotoxicity against HuH7 cells Cytotoxicity against HuH7 cells	[PMID: 20857959]
Huh-7	CC₅₀	>200 μg/mL Compound: 3-TC	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 20863701]
Huh-7	CC₅₀	0.1 μM Compound: 3TC	Cytotoxicity against human HuH7 cells after 4 days by neutral red dye uptake assay Cytotoxicity against human HuH7 cells after 4 days by neutral red dye uptake assay	[PMID: 21333535]
Huh-7	EC₅₀	0.1 μM Compound: 3TC	Antiviral activity against Hepatitis B virus infected in human Huh7 cells assessed as reduction in viral DNA after 1 day by Southern blotting Antiviral activity against Hepatitis B virus infected in human Huh7 cells assessed as reduction in viral DNA after 1 day by Southern blotting	[PMID: 21333535]
Huh-7	CC₅₀	>300 μM Compound: Lamivudine	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 23237841]
Huh-7	EC₅₀	>500 μM Compound: Lamivudine	Antiviral activity against entecavir-resistant Hepatitis B virus harboring L180M/M204V/S202G triple mutant infected in human HuH7 cells Antiviral activity against entecavir-resistant Hepatitis B virus harboring L180M/M204V/S202G triple mutant infected in human HuH7 cells	[PMID: 23237841]
Huh-7	EC₅₀	0.056 μM Compound: Lamivudine	Antiviral activity against wild type Hepatitis B virus infected in human HuH7 cells Antiviral activity against wild type Hepatitis B virus infected in human HuH7 cells	[PMID: 23237841]
L1210	IC₅₀	>250 μM Compound: 5, 3TC	Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis	[PMID: 24177359]
L1210	IC₅₀	>250 μM Compound: 5, 3TC	Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis	[PMID: 24177359]
MOLT-3	CC₅₀	5.94 μg/mL Compound: 3TC	Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay	[PMID: 21334901]
MOLT-4	EC₅₀	>100 μM Compound: LVD	Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay	[PMID: 18316521]
MT2	EC₅₀	>10 μM Compound: LVD	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells	[PMID: 18316521]
MT2	EC₅₀	0.04 μM Compound: LVD	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.04 μM Compound: LVD	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells	[PMID: 18316521]
MT2	EC₅₀	0.047 μM Compound: LVD	Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.063 μM Compound: LVD	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.086 μM Compound: LVD	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.105 μM Compound: LVD	Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.171 μM Compound: LVD	Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.182 μM Compound: LVD	Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.183 μM Compound: LVD	Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.202 μM Compound: LVD	Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.219 μM Compound: LVD	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.372 μM Compound: LVD	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.462 μM Compound: LVD	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.554 μM Compound: LVD	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.667 μM Compound: LVD	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.927 μM Compound: LVD	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.969 μM Compound: LVD	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	1.14 μM Compound: LVD	Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay	[PMID: 18316521]
MT2	EC₅₀	1.259 μM Compound: LVD	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	1.683 μM Compound: LVD	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	1.985 μM Compound: LVD	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	2.445 μM Compound: LVD	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	2.47 μM Compound: LVD	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	3.247 μM Compound: LVD	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	IC₅₀	0.6 μM Compound: 3TC	Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication	[PMID: 19596885]
MT2	EC₅₀	0.8 μM Compound: Lamivudine	Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis	[PMID: 21115794]
MT2	EC₅₀	0.8 μM Compound: Lamivudine	Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis	[PMID: 21115794]
MT2	EC₅₀	0.8 μM Compound: Lamivudine	Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I, K82N mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysi Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I, K82N mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysi	[PMID: 21115794]
MT2	EC₅₀	0.8 μM Compound: Lamivudine	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR	[PMID: 21115794]
MT4	CC₅₀	>44 μM Compound: 3TC (2'-deoxy-3'thiacytidine)	In vitro concentration required to cause death of uninfected MT-4 cell In vitro concentration required to cause death of uninfected MT-4 cell	[PMID: 12852943]
MT4	EC₅₀	0.4 μM Compound: 3TC (2'-deoxy-3'thiacytidine)	In vitro concentration required to inhibit the cytopathicity of HIV-1 IIIB on MT-4 cell In vitro concentration required to inhibit the cytopathicity of HIV-1 IIIB on MT-4 cell	[PMID: 12852943]
MT4	CC₅₀	>44 μM Compound: 3TC	Concentration required to cause death of MT-4 cells was determined in vitro Concentration required to cause death of MT-4 cells was determined in vitro	[PMID: 14971898]
MT4	EC₅₀	0.5 μM Compound: 3TC	Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro	[PMID: 14971898]
MT4	CC₅₀	>87 μM Compound: 3TC	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24119448]
MT4	EC₅₀	1.8 μM Compound: 3TC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay	[PMID: 24119448]
MT4	EC₅₀	5.9 μM Compound: 3TC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay	[PMID: 24119448]
MT4	CC₅₀	>87.2 μM Compound: 3TC	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 24794751]
MT4	EC₅₀	2.442 μM Compound: 3TC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	7.2 μM Compound: 3TC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	CC₅₀	>87 μM Compound: lamivudine	Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	15.5 μM Compound: lamivudine	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	3.9 μM Compound: lamivudine	Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	CC₅₀	>87.24 μM Compound: Lamivudine	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	15.53 μM Compound: Lamivudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	3.89 μM Compound: Lamivudine	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	CC₅₀	>87.24 μM Compound: 3 TC	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	2.22 μM Compound: 3 TC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	8.81 μM Compound: 3 TC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	>87.24 μM Compound: 3TC	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	EC₅₀	2.24 μM Compound: 3TC	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	8.79 μM Compound: 3TC	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	CC₅₀	>87 μM Compound: 3 TC	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	2239 nM Compound: 3 TC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	0.89 μM Compound: Lamivudine	Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	EC₅₀	3.56 μM Compound: Lamivudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	CC₅₀	>87 μM Compound: 3 TC	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	2.2 μM Compound: 3 TC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	>87 μM Compound: lamivudine	Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay	[PMID: 25946116]
MT4	EC₅₀	15.5 μM Compound: lamivudine	Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	3.9 μM Compound: lamivudine	Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	CC₅₀	20 μg/mL Compound: Lamivudine	Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 27105027]
MT4	IC₅₀	0.58 μg/mL Compound: Lamivudine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 27105027]
MT4	CC₅₀	>87.2 μM Compound: 3TC	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	3.1 μM Compound: 3TC	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	CC₅₀	>87240 nM Compound: 3TC	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	2240 nM Compound: 3TC	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	8790 nM Compound: 3TC	Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	>87.2 μM Compound: 3TC	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27748590]
MT4	EC₅₀	2.22 μM Compound: 3TC	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27748590]
MT4	EC₅₀	8.81 μM Compound: 3TC	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27748590]
MT4	CC₅₀	>87.2 μM Compound: 3TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28659246]
MT4	CC₅₀	>42 μM Compound: 3TC	Cytotoxicity in human MT4 cells expressing GFP assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay Cytotoxicity in human MT4 cells expressing GFP assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay	[PMID: 30265808]
MT4	CC₅₀	>87.3 μM Compound: 3TC	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30606670]
MT4	CC₅₀	>87.2 μM Compound: 3TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30721060]
MT4	CC₅₀	>87.24 μM Compound: 3 TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31434039]
MT4	CC₅₀	>7.5 μM Compound: Lamivudine	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	[PMID: 31767136]
MT4	CC₅₀	>87.2 μM Compound: 3TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32977301]
MT4	CC₅₀	>87.24 μM Compound: 3TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 33279288]
MT4	CC₅₀	>20 μM Compound: 3 TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 34583311]
MT4	CC₅₀	>87240 nM Compound: 3TC	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34890994]
MT4	CC₅₀	>87.24 μM Compound: 3TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 35754374]
MT4	CC₅₀	>87.3 μM Compound: 3 TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 35780636]
MT4	CC₅₀	>87 μM Compound: Lamivudine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay	[PMID: 36640458]
MT4	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 38954919]
MT4	IC₅₀	>100 μg/mL Compound: 3TC	Cytotoxicity against uninfected MT-4 cells Cytotoxicity against uninfected MT-4 cells	[PMID: 7538590]
MT4	IC₅₀	0.043 μg/mL Compound: 3TC	Antiviral activity against HIV-1 (strain RF) infected MT-4 cells Antiviral activity against HIV-1 (strain RF) infected MT-4 cells	[PMID: 7538590]
MT4	IC₅₀	0.048 μg/mL Compound: 3TC	Antiviral activity against HIV-1 resistant to 2-(2-Benzoyl-4-chloro-phenyl)-N-[4-(3-dimethylamino-propoxy)-2-methyl-phenyl]-acetamide in MT-4 cells Antiviral activity against HIV-1 resistant to 2-(2-Benzoyl-4-chloro-phenyl)-N-[4-(3-dimethylamino-propoxy)-2-methyl-phenyl]-acetamide in MT-4 cells	[PMID: 7538590]
MT4	IC₅₀	0.1 μM Compound: 1	Concentration required to inhibit syntica formation by 50% in HIV-1 infected MT-4 cells Concentration required to inhibit syntica formation by 50% in HIV-1 infected MT-4 cells	[PMID: 8035429]
MT4	CC₅₀	100 μM Compound: 3TC	Compound was tested for its cytotoxicity against HIV-1 infected MT-4 cell lines Compound was tested for its cytotoxicity against HIV-1 infected MT-4 cell lines	10.1016/0960-894X(96)00316-2
MT4	IC₅₀	0.1 μM Compound: 3TC	Compound was tested to inhibit HIV-1 replication in MT-4 cell lines Compound was tested to inhibit HIV-1 replication in MT-4 cell lines	10.1016/0960-894X(96)00316-2
MT4	EC₅₀	7 μM Compound: 1a	Compound was tested for its anti-HIV activity in acutely infected MT-4 cells Compound was tested for its anti-HIV activity in acutely infected MT-4 cells	10.1016/S0960-894X(01)81256-7
MT4	CC₅₀	405 μM Compound: (+/-) 3TC	Antiviral activity in MT-4 cells expressed as CC50 Antiviral activity in MT-4 cells expressed as CC50	10.1016/S0960-894X(97)00178-9
MT4	CC₅₀	407 μM Compound: 3TC	Cytotoxicity against MT-4 cells Cytotoxicity against MT-4 cells	10.1016/S0960-894X(97)00178-9
MT4	IC₅₀	0.37 μM Compound: 3TC	Antiviral activity in MT-4 cells Antiviral activity in MT-4 cells	10.1016/S0960-894X(97)00178-9
PBMC	CC₅₀	>10 μM Compound: 3TC	Concentration required to cause death of PBMC cells was determined in vitro Concentration required to cause death of PBMC cells was determined in vitro	[PMID: 14971898]
PBMC	EC₅₀	11.6 nM Compound: 3TC	Effective concentration to inhibit HIV-1 LAI cytopathicity in PBMC cells was determined in vitro Effective concentration to inhibit HIV-1 LAI cytopathicity in PBMC cells was determined in vitro	[PMID: 14971898]
PBMC	EC₅₀	>100 μM Compound: 3TC	In vitro effective concentration against Lamivudine resistant HIV-1 mutant M184V in human peripheral blood mononuclear cells In vitro effective concentration against Lamivudine resistant HIV-1 mutant M184V in human peripheral blood mononuclear cells	[PMID: 15916425]
PBMC	EC₅₀	0.027 μM Compound: 3TC	In vitro effective concentration against Lamivudine resistant wild type HIV-1 in human peripheral blood mononuclear cells In vitro effective concentration against Lamivudine resistant wild type HIV-1 in human peripheral blood mononuclear cells	[PMID: 15916425]
PBMC	EC₅₀	0.04 μM Compound: LVD	Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.071 μM Compound: LVD	Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.081 μM Compound: LVD	Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.85 μM Compound: LVD	Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	CC₅₀	52.97 μg/mL Compound: 3TC	Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay	[PMID: 21334901]
PBMC	IC₅₀	>100 μM Compound: 3TC, Epivir	Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay	[PMID: 21700368]
PBMC	CC₅₀	>13097 nM Compound: 1, lamivudine, 3TC	Cytotoxicity against PHA-stimulated human PBMC incubated for 6 hrs followed by compound-wash out measured after 6 days Cytotoxicity against PHA-stimulated human PBMC incubated for 6 hrs followed by compound-wash out measured after 6 days	[PMID: 22533850]
PBMC	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human PBMC assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay Cytotoxicity against human PBMC assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay	[PMID: 28094179]
PBMC	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human PBMC by CellTiter 96 non-radioactive cell proliferation colorimetric assay Cytotoxicity against human PBMC by CellTiter 96 non-radioactive cell proliferation colorimetric assay	[PMID: 28688280]
PBMC	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay	[PMID: 33421915]
TZM	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38954919]
Vero	IC₅₀	>100 μM Compound: 3TC	In vitro cytotoxicity against Vero cells In vitro cytotoxicity against Vero cells	[PMID: 11052795]
Vero	CC₅₀	>100 μg/mL Compound: 1a (Lamivudine)	Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay	[PMID: 11677126]
Vero	CC₅₀	>100 μg/mL Compound: 3-TC(Lamivudine)	Cytotoxic concentration required to reduce the viability of Vero cells as determined by MTT assay Cytotoxic concentration required to reduce the viability of Vero cells as determined by MTT assay	[PMID: 11985471]
Vero	IC₅₀	>100 μM Compound: 3TC, Epivir	Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry	[PMID: 21700368]
Vero	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay	[PMID: 28094179]
Vero	CC₅₀	>100 μM Compound: 3TC	Cytotoxicity against African green monkey Vero cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay Cytotoxicity against African green monkey Vero cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay	[PMID: 28688280]
Vero	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 33421915]
Vero	IC₅₀	>100 μM Compound: 26 (+)-beta	Inhibition of cell growth in vero cells Inhibition of cell growth in vero cells	[PMID: 8410975]
Vero	IC₅₀	>100 μM Compound: [(2S,5R)-BCH-189]	Cytotoxicity was determined in the vero cells infected with HIV-I Cytotoxicity was determined in the vero cells infected with HIV-I	[PMID: 8423591]
Vero	IC₅₀	>100 μM Compound: 3TC	Toxic activity against VERO cells. Toxic activity against VERO cells.	[PMID: 9301659]
Vero	IC₅₀	>100 μM Compound: 1a	Compound was tested for its cytotoxic activity in uninfected Vero cells Compound was tested for its cytotoxic activity in uninfected Vero cells	10.1016/S0960-894X(01)81256-7
WI-38	CC₅₀	>100 μM Compound: Lamivudine	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	>100 μM Compound: Lamivudine	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

体外実験

Lamivudine (1 μM) is potent inhibitor of hepatitis B virus (HBV) replication, shows antiviral activity in primary duck hepatocyte (PDH) cultures derived from ducklings congenitally infected with the duck hepatitis B virus (DHBV)^[1].
Lamivudine (0-20 μM; 2, 4, 9 d) inhibits DHBV replication with 50% inhibitory concentration of 0.55 μM^[1].
Lamivudine, combinded with penciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine [PCV]), (1 μM; 2, 4, 9 d) shows synergistic effect, acts potent function in reducing the normally recalcitrant viral covalently closed circular (CCC) DNA form of DHBV^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Lamivudine (20-500 mg/kg/d; p.o.; 15 or 45 d) causes oxidative stress and is toxic to rat liver^[2].
Lamivudine (50 mg/kg; i.p.; single dose) penetrates well in CNS and localizes in brain regions susceptible to HIV neurodegeneration in rat^[3].
Pharmacokinetic Parameters of Lamivudine in HIV-infected Rats^[3]

Parameter	C_max (μg/mL)	T_max (h)	T_1/2 (h)	AUC (h·ng/mL)
Plasma	25,846	0.25	0.68	22,172
Brain	272	0.5	1.2	967

Pharmacokinetic data measured over a 24-h period, sampling was done at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, and 24.0 h postdose.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar female rats^[2]
Dosage:

20-500 mg/kg/day
Administration:

Oral gavage; single or repeated dose; 15 or 45 days
Result:

Increased activities of the aminotransferases (ALT and AST), γ-glutamyltransferase (GGT) and total protein concentration in serum at 500 mg/kg dose.
Increased activities of glutathione S-transferase (GST), GGT and superoxide dismutase (SOD) as well as concentrations of malondialdehyde (MDA) and protein at 20 mg/kg dose.
Caused multifocal lymphocyte population and hepatocyte edema degeneration in hepatic sinusoids of chickens.

化学情報

CAS 番号 134678-17-4
性状 Solid
分子量 229.26
分子式 C₈H₁₁N₃O₃S
Color White to off-white
SMILES

OC[C@H]1SC[C@@H](N2C(N=C(N)C=C2)=O)O1
別名

Lamivudine; BCH-189
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (19)

All Cell Imaging/StainingBio/Physico-chemical AssayWBHistological Imaging/StainingIHC

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Inhibition of long interspersed nuclear element-1 by nucleoside reverse transcriptase inhibitors attenuates vascular calcification. [Abstract]

2025 Oct 1;10(1):321. PMID: 41027876

Lamivudine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 1;10(1):321. [Abstract]

VSMCs were treated with Pi and NRTIs (Lamivudine, 1, 5, 10, or 50 μM), followed by Alizarin Red staining.

Lamivudine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 1;10(1):321. [Abstract]

VSMCs treated with Pi and NRTIs (Lamivudine, 1, 5, 10, or 50 μM). followed by calcium content.

Lamivudine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 1;10(1):321. [Abstract]

Western blot analysis expression of Runx2, OPN, Smoothelin, SM22α, and LINE1-ORF1 in VSMCs treated with Pi and NRTIs.

Lamivudine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 1;10(1):321. [Abstract]

Serum creatinine levels in CKD mice treated with NRTIs (Lamivudine, 1 mg/kg, administered daily intraperitoneal injections).

Lamivudine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 1;10(1):321. [Abstract]

NRTIs (Lamivudine, 1 mg/kg, administered daily intraperitoneal injections). Aortic cross-sections from CKD mice or VitD3-overloaded mice were stained using Von Kossa, with n = 3 per group; scale bar = 100 μm.

Lamivudine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 1;10(1):321. [Abstract]

NRTIs (Lamivudine, 1 mg/kg, administered daily intraperitoneal injections). Calcium content analysis of aortas from CKD mice or VitD3-overloaded mice (n = 5 per group).

Lamivudine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 1;10(1):321. [Abstract]

NRTIs (Lamivudine, 1 mg/kg, administered daily intraperitoneal injections). Immunohistochemical staining of Runx2 and LINE1-ORF1 from CKD mice or VitD3-overloaded mice (n = 3 per group); scale = 50 μm.

Lamivudine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 1;10(1):321. [Abstract]

NRTIs (Lamivudine, 1 mg/kg, administered daily intraperitoneal injections). Osteogenic and contractile phenotypic markers, as well as LINE1-ORF1, were analyzed through Western blot and quantitative in CKD mice (n = 3 per group).
Cell

Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo. [Abstract]

2025 Sep 4;188(18):4896-4912.e19. PMID: 40645177
Nat Aging

Targeting age-related LINE-1 activation alleviates cardiac aging. [Abstract]

2026 Feb;6(2):414-429. PMID: 41571992
Aging Cell

Systemic LINE-1 RNA in Plasma Extracellular Vesicles Drives Neuroinflammation and Cognitive Dysfunction via cGAS-STING Pathway in Aging. [Abstract]

2026 Jan;25(1):e70350. PMID: 41480826
Phytother Res

Anti-hepatitis B virus activity and hepatoprotective effect of des(rhamnosyl) verbascoside from Lindernia ruellioides in vitro. [Abstract]

2021 Aug;35(8):4555-4566. PMID: 34146352
Int J Mol Sci

Triterpenoids CDDO and CDDO-EA Inhibit the Replication of Hepatitis B Virus by Modulating Nucleocapsid Assembly. [Abstract]

2025 Dec 27;27(1):300. PMID: 41516181
Eur J Pharmacol

Astragalin inhibits hepatitis B virus through functional reconstitution of CD8+ T cells and a direct effect on HBV control. [Abstract]

2025 Aug 29:1005:178108. PMID: 40886877
J Med Virol

Dynamics of Serum Hepatitis B Virus Nucleic Acids in Patients With Chronic Hepatitis B After Stopping Nucleos(t)ide Analogs Reveal Delayed Rebound of Hepatitis B Virus RNA. [Abstract]

2026 Jan;98(1):e70764. PMID: 41439722
Molecules

(-)-Lariciresinol Isolated from the Roots of Isatis indigotica Fortune ex Lindl. Inhibits Hepatitis B Virus by Regulating Viral Transcription. [Abstract]

2022 May 18;27(10):3223. PMID: 35630700
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
J Cell Mol Med

Lamivudine improves cognitive decline in SAMP8 mice: Integrating in vivo pharmacological evaluation and network pharmacology. [Abstract]

2021 Sep;25(17):8490-8503. PMID: 34374199
Biomedicines

Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings. [Abstract]

2022 Jan 26;10(2):268. PMID: 35203482
Virol J

Sophora alopecuroides biflavones glycoside, isolated from Sophora alopecuroides, inhibits the secretion of hepatitis B virus surface antigen through direct interaction with its antigenic loop domain. [Abstract]

2025 Oct 27;22(1):342. PMID: 41146264
ACS Infect Dis

Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]

2025 Oct 30. PMID: 41166549
ASN Neuro

Exposure to Frontline Antiretroviral Dolutegravir Disrupts Oligodendrocyte Development Across Differentiation Stages. [Abstract]

2026;18(1):2647877. PMID: 41904696
Mol Med Rep

Identification of metabolites associated with capecitabine‑induced hand‑foot syndrome using untargeted metabolomics in patients with cancer. [Abstract]

2025 Jul;32(1):203. PMID: 40377002
J Clin Virol

Impact of metformin on HBV replication: No evidence of suppression in vitro. [Abstract]

2025 Apr:177:105781. PMID: 40120569
Front Oncol

Gut virome dysbiosis impairs antitumor immunity and reduces 5-fluorouracil treatment efficacy for colorectal cancer. [Abstract]

2024 Dec 19:14:1501981. PMID: 39791120
Virus Res

Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. [Abstract]

2019 Oct 2:271:197677. PMID: 31376401

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (218.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 50 mg/mL (218.09 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3619 mL

21.8093 mL

43.6186 mL

5 mM

0.8724 mL

4.3619 mL

8.7237 mL

10 mM

0.4362 mL

2.1809 mL

4.3619 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (436.19 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (281 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26(1):216-25. [Content Brief]

[2]. Olaniyan LW, et al. Lamivudine-Induced Liver Injury. Open Access Maced J Med Sci. 2015 Dec 15;3(4):545-50. [Content Brief]

[3]. Mdanda S, et al. Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. Assay Drug Dev Technol. 2019 Oct;17(7):322-329. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	4.3619 mL	21.8093 mL	43.6186 mL	109.0465 mL
	5 mM	0.8724 mL	4.3619 mL	8.7237 mL	21.8093 mL
	10 mM	0.4362 mL	2.1809 mL	4.3619 mL	10.9047 mL
	15 mM	0.2908 mL	1.4540 mL	2.9079 mL	7.2698 mL
	20 mM	0.2181 mL	1.0905 mL	2.1809 mL	5.4523 mL
	25 mM	0.1745 mL	0.8724 mL	1.7447 mL	4.3619 mL
	30 mM	0.1454 mL	0.7270 mL	1.4540 mL	3.6349 mL
	40 mM	0.1090 mL	0.5452 mL	1.0905 mL	2.7262 mL
	50 mM	0.0872 mL	0.4362 mL	0.8724 mL	2.1809 mL
	60 mM	0.0727 mL	0.3635 mL	0.7270 mL	1.8174 mL
	80 mM	0.0545 mL	0.2726 mL	0.5452 mL	1.3631 mL
	100 mM	0.0436 mL	0.2181 mL	0.4362 mL	1.0905 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Lamivudine

19 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ラミブジン

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Classic FDA-Approved Drug Library

3D Diverse Fragment Library

MedChemExpress（MCE）の使用を引用している文献 Lamivudine

HIV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (19)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Lamivudine 関連分類

HY-B0250 関連分類